Every 424B that MoonLake Immunotherapeutics (MLTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MLTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLTX filings page.
MoonLake Immunotherapeutics is conducting a registered offering of 9,000,000 Class A Ordinary Shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 1,000,000 Class A Ordinary Shares at a public offering price of $20.00 per share. Delivery is expected on June 25, 2026. The prospectus estimates net proceeds of approximately $188.8 million (or about $217.1 million if the underwriters’ option to purchase up to 1,500,000 additional shares is exercised in full). Proceeds are planned to fund development, pre-commercialization and potential commercialization of Sonelokimab (“SLK”), with stated runway to mid-2028 if approved and assuming current plans. The offering includes customary underwriting discounts and a lock-up period for certain insiders.
MoonLake Immunotherapeutics is offering securities under a preliminary prospectus supplement for an aggregate offering amount of $150,000,000. The offering covers Class A Ordinary Shares and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.0001 per share. The underwriters have a 30‑day option to purchase up to $22,500,000 of additional Class A Ordinary Shares. The prospectus cites 72,134,066 Class A Ordinary Shares outstanding as of March 31, 2026 and discloses a last reported Nasdaq sale price of $22.16 on June 22, 2026. Net proceeds are intended to fund continued development and (if approved) commercialization of SLK (Sonelokimab) and for general corporate purposes. The prospectus supplement notes clinical Phase 3 VELA program results for SLK in hidradenitis suppurativa and discusses risks, dilution, PFIC tax considerations and limits on pre-funded warrant exercisability.
MoonLake Immunotherapeutics is offering 7,142,857 Class A Ordinary Shares at $10.50 per share pursuant to a prospectus supplement. The company estimates net proceeds of approximately $72.6 million after underwriting discounts and offering expenses, to be used to fund research and development of SLK and for general corporate purposes. The company expects these funds, together with existing cash and investments, to be sufficient to fund its planned Phase 3 clinical trial in PPP.
Gross proceeds are $74,999,999, with underwriting discounts and commissions of $2,250,000. Shares outstanding were 64,230,722 as of September 30, 2025, and are expected to be 71,373,579 after this offering. New investors will experience immediate dilution of $5.40 per share based on the as adjusted net tangible book value as of September 30, 2025. A 60‑day lock‑up applies to the company, directors, officers and certain holders. MLTX last traded at $10.13 on November 4, 2025. Leerink Partners is the sole bookrunning manager, with delivery expected on or about November 6, 2025.